FDA Removes HRT Black Box Warning: What Charleston Women Need
By Ashley Harwyn, PA-C, Board Certified in Anti-Aging and Functional Medicine (A4M) | Published May 27, 2026 | Last updated May 27, 2026
On February 12, 2026, the U.S. Food and Drug Administration removed the black box warning from six menopausal hormone therapy products[1]. For Charleston women who have spent two decades hearing that hormone replacement therapy is dangerous, this matters: the FDA's most prominent safety warning, in place since 2003, no longer says estrogen-containing therapy raises the risk of cardiovascular disease, breast cancer, or probable dementia for the women most likely to benefit from it.
DIRECT ANSWER
What the FDA actually changed: warnings about cardiovascular disease, breast cancer, and probable dementia were removed from the boxed warning section of six HRT products, including combined estrogen-progesterone, systemic estrogen-alone, systemic progestogen-alone, and topical vaginal estrogen[1]. The endometrial cancer warning still applies to systemic estrogen-alone in women with an intact uterus, so that exclusion has not changed. What no other Charleston discussion of this news has covered is what the change does NOT do, and the clinical framework I use at Solcara to identify which Lowcountry women are genuinely ready to revisit HRT now.
I've practiced functional medicine and hormone optimization in Mount Pleasant since founding Solcara Health, and at our new location inside The Longevity Club in downtown Charleston. The women coming to us in 2026 are different from the ones who came five years ago. They've read Mary Claire Haver. They've listened to Stacy Sims. They've already heard about the WHI re-analysis. What they want now is a Charleston provider who'll treat the decision as the clinical decision it actually is, not a regulatory landmine.
KEY TAKEAWAYS
→
The FDA removed boxed warnings about cardiovascular disease, breast cancer, and probable dementia from six menopausal hormone therapy products on February 12, 2026.
→
The endometrial cancer warning for systemic estrogen-alone in women with an intact uterus has NOT been removed.
→
The change reflects the WHI re-analysis on timing: women who start HRT within ten years of menopause or before age 60 see different outcomes than those who started decades later.
→
Some women are still poor candidates for HRT regardless of the labeling change, especially those with personal history of estrogen-receptor-positive breast cancer or active venous thromboembolism.
→
I use a Three-Question HRT Readiness Check at Solcara to assess candidacy quickly. This article walks you through it.
Section 01 / The Action
What the FDA actually did in February 2026
On February 12, 2026, the FDA formally approved drug labeling changes on six menopausal hormone therapy products, removing risk statements related to cardiovascular disease, breast cancer, and probable dementia from the boxed warning section[1]. The action followed a public review process the U.S. Department of Health and Human Services initiated in November 2025[2]. The updated labels affect four product categories explained below.
6
HRT products updated
4
product categories
29
drug companies filed
23
years the warning stood
The four categories are: combined estrogen and progesterone therapy, systemic estrogen-alone therapy, systemic progestogen-alone therapy used with estrogen in women with a uterus, and topical vaginal estrogen[1].
CITATION CAPSULE
The FDA's February 12, 2026 action removed cardiovascular disease, breast cancer, and probable dementia warnings from the boxed warning section of six menopausal hormone therapy products covering four categories: combined estrogen-progesterone, systemic estrogen-alone, systemic progestogen-alone for women with a uterus, and topical vaginal estrogen[1]. The endometrial cancer warning on systemic estrogen-alone in women with an intact uterus remains in place.
This is not a minor footnote update. The boxed warning is the FDA's most prominent safety designation, the literal black box rectangle on the prescribing information. Twenty-nine drug companies submitted proposed labeling changes at the FDA's request to make this change happen[2].
"Women face symptoms of menopause that can last for years, and our efforts will help these women make well-informed medical decisions."
FDA Commissioner Martin Makary, February 12, 2026[1]
HHS Secretary Robert F. Kennedy Jr. said the action "reflects our commitment to follow the science wherever it leads"[1]. For most Charleston women who have been considering HRT but hit hesitation at the prescriber's office, this is the regulatory signal you've been waiting for.
Section 02 / The History
Why the black box warning existed in the first place
The original black box warning was added in 2003, in response to the 2002 publication of initial results from the Women's Health Initiative (WHI), the largest randomized trial of hormone therapy ever conducted[3]. The WHI enrolled more than 27,000 women across two trials: combined estrogen plus progestin in women with a uterus, and estrogen-alone in women who had undergone hysterectomy.
When the early WHI data showed increased risks of breast cancer in the combined arm, the FDA acted quickly, adding the boxed warning. For two decades after, the warning told every prescriber and every patient that estrogen-containing menopause therapy raised serious risks. In Charleston, like everywhere else, women in their fifties and sixties were quietly steered away from HRT by primary care doctors and even some gynecologists. Many women who would have benefited never started. Many who'd been doing well were taken off.
A 63-year-old woman just starting HRT and a 51-year-old woman just starting HRT are not the same patient.
What the original WHI report didn't adequately convey was that the average age of women enrolled was 63, well past the menopausal transition for most participants. The original analysis treated them as one population. Twenty years of follow-up data has clarified that picture.
Book a Longevity Consult at Solcara
If you've been waiting for clarity on HRT, this is the moment to get a personalized clinical assessment from a board-certified anti-aging practitioner.
In 2017, the WHI investigators published a long-term follow-up analyzing 18 years of cumulative data across both trial arms[4]. The picture was different. Women who initiated hormone therapy within ten years of menopause onset or before age sixty showed different cardiovascular outcomes than older starters. The original interpretation had collapsed a heterogeneous population into a single risk number.
CITATION CAPSULE
The Women's Health Initiative cumulative 18-year follow-up published in JAMA in 2017 found that all-cause mortality and cardiovascular outcomes for women starting hormone therapy within ten years of menopause or before age 60 were notably different from outcomes in women starting later[4]. The FDA's February 2026 labeling change explicitly references this timing finding, noting that women who initiate HRT within 10 years from the beginning of menopause, particularly before age 60, saw a reduction in all-cause mortality and fractures[1].
This is what's now called the timing hypothesis. Estrogen acts differently on younger vascular tissue than on older vascular tissue. The earlier the start, the more likely the benefit picture is to outweigh the risk picture for an appropriate candidate. The North American Menopause Society's 2022 position statement on hormone therapy reflects this evidence base[5], as does the AHA's 2020 Scientific Statement on the menopause transition and cardiovascular disease[6].
In my Mount Pleasant practice, the women who benefit most are typically in the 45-58 window, recently postmenopausal, with vasomotor symptoms or genitourinary symptoms that are interfering with sleep, sexual function, or cognitive performance. They tend to have intact metabolic markers, no personal history of estrogen-receptor-positive breast cancer, and no active venous thromboembolism. For those women, the FDA's February 2026 update reflects what the clinical evidence has been saying for years.
Section 04 / What Changed, What Didn't
What changed in February 2026 and what did NOT change
The labeling change is significant but narrow. It removes specific warnings about cardiovascular disease, breast cancer, and probable dementia from the boxed warning section[1]. It does not say HRT is universally safe. It does not eliminate individualized contraindications. It does not change the underlying physiology of estrogen-receptor-positive cancer biology.
WHAT DID NOT CHANGE
The endometrial cancer warning on systemic estrogen-alone in women with an intact uterus remains in place[1].
Personal history exclusions still apply: ER-positive breast cancer history, unexplained vaginal bleeding, active venous thromboembolism, severe liver disease, untreated CAD.
Existing FDA disclosure language outside the boxed warning still applies.
Local hospital protocols may lag the FDA's updated labels.
WHAT DID CHANGE
The FDA's most prominent safety designation has been recalibrated for the appropriate-candidate population.
The conversation with your prescriber can shift from "this is dangerous" to "let's evaluate your individual risk-benefit picture."
All four product categories received the same updated labeling[1].
A new clinical baseline for the next decade of women's longevity decisions.
What I see most often in my Mount Pleasant office is confusion about which category a woman falls into. A patient on a topical vaginal estrogen for genitourinary symptoms had been worried for years that she was running the same cardiovascular risk as systemic combined therapy. She wasn't. She'd been hedged out of her own quality of life by a warning that, in her case, never even applied. The February 2026 update makes that mismatch easier to spot.
Section 05 / The Readiness Check
Who can reconsider HRT now and who still should not
In my practice at Solcara, I use a Three-Question HRT Readiness Check before any clinical decision is finalized. This is the framework that's saved my patients the most time, and it tracks closely to the criteria the FDA's February 2026 update implicitly endorses.
Ashley Harwyn, PA-C · Founder, Solcara Health · Board Certified in Anti-Aging & Functional Medicine (A4M)
INTERACTIVE / TAKE THE CHECK
The Three-Question HRT Readiness Check
Answer three questions to see whether HRT is a real conversation for you.
1
TIMING
Are you within 10 years of menopause, or under age 60?
2
UTERUS & PROGESTERONE
Do you have an intact uterus, and if so, are you open to taking progesterone with any systemic estrogen?
3
PERSONAL-HISTORY EXCLUSIONS
Do any of these apply to you?
Estrogen-receptor-positive breast cancer history
Unexplained vaginal bleeding
Active or recent blood clots (legs or lungs)
Severe active liver disease
Untreated coronary artery disease
✓
You're a strong candidate for the conversation.
Based on your answers, you clear all three readiness criteria. The FDA's February 2026 update applies to your situation. The next step is a proper clinical workup with a provider who is current on the new labeling.
◐
There's a conversation worth having.
Your situation has nuance. Outside the standard timing window, alternative routes (topical vaginal estrogen, non-hormonal options) may still apply. If you'd rather not take progesterone, non-systemic options remain on the table. A proper clinical workup will clarify your individual benefit-risk picture.
⚑
Your situation requires a careful workup.
One or more personal-history items on your list means the FDA labeling change does not automatically apply to you. This doesn't mean HRT is off the table. It means the decision needs an individual review. We do these reviews at Solcara every week.
This check is an educational tool, not a medical assessment. It does not capture every factor a clinician would consider. Use it to start the conversation, not finish it.
Reference graphic for printing or sharing:
The Three-Question HRT Readiness Check by Ashley Harwyn, PA-C. Embeddable with attribution.
Question 1: Are you within ten years of your final menstrual period, or under age 60?
The WHI re-analysis[4] and the FDA's 2026 update[1] both emphasize timing. The closer to menopause the initiation, the more favorable the outcome data tends to be. If you're 47 and just started skipping periods, the answer is almost always yes. If you're 71 and have been postmenopausal for two decades, the picture changes.
Question 2: Do you have an intact uterus, and if so, are you prepared to take progesterone with any estrogen?
The endometrial cancer warning has not changed[1]. If you have a uterus and want systemic estrogen, you need progesterone for endometrial protection. Non-negotiable. Topical vaginal estrogen is the exception, but for any systemic estrogen the rule still holds.
Question 3: Have you cleared the personal-history exclusions?
This includes: history of estrogen-receptor-positive breast cancer, unexplained vaginal bleeding, active or recent venous thromboembolism (blood clots in the legs or lungs), severe active liver disease, and untreated coronary artery disease. A single yes on this list doesn't necessarily disqualify, but it does require a more careful workup.
CITATION CAPSULE
The North American Menopause Society's 2022 Hormone Therapy Position Statement remains the authoritative clinical reference for prescriber decision-making in the United States[5]. NAMS recommends individualized hormone therapy decisions based on age, time since menopause, baseline cardiovascular and cancer risk, and presenting symptoms. The FDA's February 2026 labeling action aligns the regulatory environment with what NAMS has recommended clinically for years.
If you can clear all three questions, the FDA's February 2026 action means your Charleston provider should be willing to have a genuine conversation about HRT. If you can't clear one, the conversation shifts to either modifying the protocol (lower dose, different route, non-systemic option) or considering non-hormonal alternatives, including newly approved options like fezolinetant (Veozah) for vasomotor symptoms.
Section 06 / The Appointment
What to ask your Charleston provider
I won't tell you which protocol to use. That decision belongs to you and your prescriber together. What I will tell you is what to ask, because the questions you bring to the appointment dictate the quality of the conversation. The five questions below are the ones I see Charleston women bring to Solcara most often, and the ones that move the appointment from a defensive posture to an actual clinical conversation.
01
Given my age, time since menopause, and history, how does my benefit-risk picture look under the FDA's February 2026 labeling?
This signals you've read the update and expect a current conversation.
02
What is your current protocol for monitoring while on HRT?
A current protocol typically includes a baseline cardiometabolic panel, breast and pelvic exam, and follow-up labs at three to six months. If your provider can't describe an active monitoring plan, that tells you something.
03
What is your view on combining HRT with metabolic optimization, especially if I'm also considering a GLP-1 medication?
This is increasingly relevant for women in the 45-58 window, and the synergy between HRT and tirzepatide or semaglutide in postmenopausal women is an active research area.
04
What about cardiovascular workup before we start, or in the first six months?
A longevity-aware provider will recommend more than a basic cholesterol panel. ApoB, Lp(a), and advanced lipid markers belong in the conversation.
05
If you're not the right provider for this, who in Charleston do you recommend?
A confident provider will refer when appropriate. A defensive one will deflect.
CITATION CAPSULE
The American Heart Association's 2020 Scientific Statement on the menopause transition and cardiovascular disease risk specifically calls out the menopausal window as a period of accelerated cardiovascular risk change in women, with implications for both timing of intervention and selection of cardiometabolic markers[6]. A current Charleston provider who is initiating or continuing HRT should be able to discuss how that decision integrates with cardiovascular risk monitoring, not just symptom relief.
In my practice, the women who walk in with these five questions get the most out of their first appointment. They're also the women most likely to leave with a clear plan rather than a vague "let's think about it."
Section 07 / Frequently Asked
Frequently asked questions about the FDA's HRT label change
The questions Charleston women bring up most often. Click any question to read Ashley's answer.
YOU ASKED
Did the FDA actually remove the black box warning from HRT?
AH
ASHLEY HARWYN, PA-C
Yes. On February 12, 2026, the FDA formally approved labeling changes on six menopausal hormone therapy products, removing risk statements about cardiovascular disease, breast cancer, and probable dementia from the boxed warning section[1]. The action followed a public process that HHS initiated in November 2025[2]. The official FDA press release describes the four product categories affected: combined estrogen-progesterone, systemic estrogen-alone, systemic progestogen-alone for women with a uterus, and topical vaginal estrogen.
YOU ASKED
Is HRT now safe for everyone?
AH
ASHLEY HARWYN, PA-C
No. The FDA action recalibrates the regulatory warning for the appropriate-candidate population, primarily women within ten years of menopause or under age 60. It does not declare HRT universally safe. Personal history exclusions still apply, including a history of estrogen-receptor-positive breast cancer, active venous thromboembolism, severe active liver disease, and untreated coronary artery disease. Individualized assessment by a qualified provider remains essential.
YOU ASKED
Does the change apply to women who already had breast cancer?
AH
ASHLEY HARWYN, PA-C
No. The labeling change does not address personal history exclusions, which are determined by the prescriber based on individual clinical factors. Women with a personal history of estrogen-receptor-positive breast cancer were not the population the FDA's update was designed for. They should continue working with their oncology team to assess any role for hormone-related therapy.
YOU ASKED
What about women who have had a hysterectomy?
AH
ASHLEY HARWYN, PA-C
Women who've had a hysterectomy can typically use systemic estrogen-alone therapy without needing progesterone for endometrial protection, because the endometrial cancer warning that remains in place applies only to women with an intact uterus[1]. The benefit-risk picture should still be evaluated individually.
YOU ASKED
Should I switch from a non-hormonal medication to HRT now that the warning has changed?
AH
ASHLEY HARWYN, PA-C
Not without a clinical conversation. If you've been on a non-hormonal medication for vasomotor symptoms (like fezolinetant) or for mood (like an SSRI) and want to discuss switching to HRT, that conversation requires your prescriber's evaluation of your full picture, including why you chose the current medication in the first place.
YOU ASKED
How do I find a Charleston provider who is current on the FDA's February 2026 update?
AH
ASHLEY HARWYN, PA-C
Look for a practitioner with current board certification in Anti-Aging and Functional Medicine (A4M) or active North American Menopause Society (NAMS) credentialing. Ask the front desk before your appointment: "Is the provider current on the FDA's February 2026 HRT labeling change?" A confident, current practice will say yes immediately. At Solcara Health, we serve Mt. Pleasant and downtown Charleston, and we've been operating under the updated framework since the labeling change went into effect.
U.S. Department of Health and Human Services. HHS Advances Women's Health, Removes Misleading FDA Warnings on Hormone Replacement Therapy. November 10, 2025. hhs.gov
Rossouw JE et al. Risks and Benefits of Estrogen Plus Progestin in Healthy Postmenopausal Women: Principal Results From the Women's Health Initiative Randomized Controlled Trial. JAMA. 2002;288(3):321-333.
Manson JE et al. Menopausal Hormone Therapy and Long-term All-Cause and Cause-Specific Mortality: The Women's Health Initiative Randomized Trials. JAMA. 2017;318(10):927-938.
The North American Menopause Society. The 2022 Hormone Therapy Position Statement of The North American Menopause Society. Menopause. 2022;29(7):767-794.
El Khoudary SR et al. Menopause Transition and Cardiovascular Disease Risk: Implications for Timing of Early Prevention. A Scientific Statement From the American Heart Association. Circulation. 2020;142(25):e506-e532.
In Closing
A clearer conversation, finally
For two decades, women in Charleston who asked about HRT got a hedge instead of an answer. The 2002 WHI publication, however well-intentioned the regulatory response, locked an entire generation of midlife women out of a therapy many of them would have benefited from. The FDA's February 12, 2026 action doesn't turn that history into nothing. It does correct the framing for the appropriate-candidate population. If you're within ten years of menopause or under age 60, if you can clear the personal-history exclusions, and if your goals include long-term healthspan rather than just symptom management, this is the moment to have the conversation you've been postponing.
At Solcara, we're running these conversations every day. We work with Charleston and Mount Pleasant women who've been waiting for the regulatory environment to catch up to the clinical evidence. The wait is over. The Three-Question HRT Readiness Check is a starting point, not a substitute for an appointment, but it tells you whether the conversation is worth having. If you're ready, we're ready. Lively up your health, finally with the regulatory clarity to do it.
Ready to revisit HRT in 2026?
Schedule a Solcara consult to walk through your individual readiness check, your full hormone panel, and your longevity-aware care plan with a board-certified anti-aging PA.
Medical Disclaimer: The information in this article is for educational purposes only and does not constitute medical advice. Hormone replacement therapy involves individual risk factors and is not appropriate for every woman. Consult a qualified healthcare provider before making any medical decisions about hormone therapy. The discussion of FDA labeling changes reflects the regulatory status as of June 2, 2026, and may be updated as additional guidance is issued.
Ashley Harwyn, PA-C, is a Board Certified Physician's Associate in Anti-Aging and Functional Medicine (A4M). Solcara Health serves patients in South Carolina from offices in Mt. Pleasant (496 Bramson Ct, Ste 120) and Downtown Charleston (163 Rutledge Ave, Ste 202, The Longevity Club).
.webp)
